文献速递淋巴瘤

弥漫大B细胞淋巴瘤的高突变基因定义不同亚型

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.
PubMed 文献 · Leukemia · 2019-06-11

研究显示体细胞超突变(SHM)模式可作为弥漫大B细胞淋巴瘤(DLBCL)分子分类标志,36个SHM靶基因表达将DLBCL分为四个新亚型。在免疫化疗患者荟萃分析中,SHM亚型与总生存(1642例)和无进展生存(795例)显著相关,且预后影响独立于细胞起源(COO)分型和国际预后指数。

要点

  • SHM模式可界定DLBCL的细胞起源(COO)。
  • 36个SHM靶基因将DLBCL分为四个新亚型。
  • SHM亚型预后影响独立于COO分型和IPI。

核心结论

  • SHM模式构成DLBCL分子分类的标志,四个SHM亚型与生存显著相关且独立于COO和IPI。

研究设计与样本

  • 研究基于体细胞超突变(SHM)模式分析,在免疫化疗患者荟萃分析中评估SHM亚型与生存的关联(总生存1642例,无进展生存795例)。

主要发现

  • SHM突变过程活性界定了DLBCL的细胞起源(COO)。
  • 36个SHM靶基因表达将DLBCL分层为四个新SHM亚型。
  • SHM亚型与总生存(1642例)和无进展生存(795例)显著相关。
  • 多因素生存分析表明SHM亚型的预后影响独立于COO分型和国际预后指数。
  • SHM亚型在每个COO亚型内以及未分类DLBCL中具有不同临床结局。

关键数值与推荐

  • 36个SHM靶基因用于将DLBCL分为四个SHM亚型。
  • 总生存分析纳入1642例患者,无进展生存分析纳入795例患者。

临床怎么用

  • SHM亚型分类可能为DLBCL提供生物学驱动的分类系统,具有潜在临床应用价值。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease whose personalized clinical management requires robust molecular stratification. Here, we show that somatic hypermutation (SHM) patterns constitute a marker for DLBCL molecular classification. The activity of SHM mutational processes delineated the cell of origin (COO) in DLBCL. Expression of the herein identified 36 SHM target genes stratified DLBCL into four novel SHM subtypes. In a meta-analysis of patients with DLBCL treated with immunochemotherapy, the SHM subtypes were significantly associated with overall survival (1642 patients) and progression-free survival (795 patients). Multivariate analysis of survival indicated that the prognostic impact of the SHM subtypes is independent from the COO classification and the International Prognostic Index. Furthermore, the SHM subtypes had a distinct clinical outcome within each of the COO subtypes, and strikingly, even within unclassified DLBCL. The genetic landscape of the four SHM subtypes indicated unique associations with driver alterations and oncogenic signaling in DLBCL, which suggests a possibility for therapeutic exploitation. These findings provide a biologically driven classification system in DLBCL with potential clinical applications.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Alkodsi A, Cervera A, Zhang K, et al. Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. Leukemia. 2019. PMID: 31186494. doi:10.1038/s41375-019-0509-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。